English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 31 May 2024, 11:00 HKT/SGT
Share:
    

Source: Kaplan Fox & Kilsheimer LLP
INARI MEDICAL, INC. (NARI) ALERT: Kaplan Fox & Kilsheimer LLP Reminds Investors of Important Deadline in Securities Fraud Class Action

NEW YORK, May 31, 2024 - (NewMediaWire) - Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) reminds investors that a complaint has been filed on behalf of purchasers of Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) common stock between February 24, 2022 and February 28, 2024 (the “Class Period”). Click Here to Join Investigation.  

If you acquired Inari common stock and have suffered losses, you may click here to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

Deadline Reminder:  If you are a member of the proposed Class, you may move the court no later than July 12, 2024 to serve as a lead plaintiff for the purported class.  If you have losses we encourage you to contact us to learn more about the lead plaintiff process. 

On February 28, 2024, after the market close, Inari Medical announced fourth quarter and full-year 2023 financial results and disclosed receipt of a civil investigative demand in December 2023 from the U.S. Department of Justice (“DOJ”) “requesting information primarily related to meals and consulting service payments provided to healthcare professionals.”  In the Company’s Annual Report filed the next day with the SEC, Inari Medical indicated that that the DOJ request was in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.

Following this news, Inari Medical stock fell $12.14 per share, about 21%, to close at $46.12 per share on February 29, 2024.

WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.  With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.  Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients.  For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

If you have any questions about this Notice, your rights, or your interests, please contact:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
E-mail: pmayer@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax:  (415) 772-4707
E-mail: lking@kaplanfox.com



Topic: Press release summary
Source: Kaplan Fox & Kilsheimer LLP

Sectors: Legal & Compliance
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 
Kaplan Fox & Kilsheimer LLP Links

http://www.kaplanfox.com

https://www.facebook.com/KaplanFoxLawFirm

https://twitter.com/kaplanfoxlaw

https://www.linkedin.com/company/kaplan-fox-&-kilsheimer-llp/

Kaplan Fox & Kilsheimer LLP Related News
Thursday, 21 November 2024, 9:00 JST
Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Aug 1, 2024 10:30 HKT/SGT
Deadline to Lead in Securities Fraud Lawsuit against ODDITY Tech Ltd. is September 17, 2024 - Contact Kaplan Fox & Kilsheimer LLP
July 31, 2024 23:15 HKT/SGT
Kaplan Fox & Kilsheimer LLP is Investigating Possible Securities Law Violations against Grifols SA (GRFS)
July 31, 2024 09:44 HKT/SGT
Kaplan Fox & Kilsheimer LLP is Investigating Grifols SA (GRFS) for Potential Securities Law Violations
July 29, 2024 21:47 HKT/SGT
Kaplan Fox & Kilsheimer LLP is Investigating Domino's Pizza Inc. (DPZ) for Possible Securities Violations
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575